Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.43
- Piotroski Score 3.00
- Grade Market Outperform
- Symbol (VOR)
- Company Vor Biopharma Inc.
- Price $0.78
- Changes Percentage (0%)
- Change -$0
- Day Low $0.76
- Day High $0.82
- Year High $3.14
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $6.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.77
- Trailing P/E Ratio -0.69
- Forward P/E Ratio -0.69
- P/E Growth -0.69
- Net Income $-117,863,000
Income Statement
Quarterly
Annual
Latest News of VOR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Will the first College Football Playoff rankings of 12-team era favor Big Ten, SEC?
The College Football Playoff Top 25 rankings for the first time with a 12-team bracket will face scrutiny due to the rise of superconferences like the SEC and Big Ten. The committee aims to evaluate t...
By The New York Times | 12 hours ago -
US Rep. John Curtis is favored to win Mitt Romney's open Senate seat in Utah
Utah voters will choose between U.S. Rep. John Curtis, a moderate Republican, and Democrat Caroline Gleich for the Senate seat previously held by Mitt Romney. Curtis focuses on a conservative approach...
By AP NEWS | 14 hours ago -
Lopsided fight to fill Feinstein's Senate seat in liberal California favors Democrat Schiff
Californians are voting for a new U.S. Senator to replace Dianne Feinstein, with Democrat Adam Schiff leading against Republican Steve Garvey. The race reflects a shift in California politics, with De...
By AP NEWS | 17 hours ago
